Targeting PSMA in Prostate Cancer Treatment

Experts review prostate cancer clinical cases and discuss approaches to treating patients with PSMA targeted therapies.

EP. 1: Initial Risk Stratification of Localized Prostate Cancer

June 10th 2022

Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.

EP. 2: Defining PSMA-PET Scans for Prostate Cancer

July 1st 2022

Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.

EP. 3: Case 1: Metastatic Castrate-Resistant Prostate Cancer

July 1st 2022

Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

EP. 4: PSMA-Positive mCRPC and the VISION Trial

July 8th 2022

Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.

EP. 5: Lutetium-PSMA-617 for Prostate Cancer Treatment

July 8th 2022

A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.

EP. 6: Radium-223 and the ALSYMPCA Trial

July 18th 2022

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

EP. 7: Case 2: Metastatic Hormone-Sensitive Prostate Cancer

July 18th 2022

Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.

EP. 8: Reviewing Data from the CARD Trial

July 26th 2022

Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.

EP. 9: mCRPC: The TheraP Trial

July 26th 2022

A review of recent data from the TheraP trial.

EP. 10: Therapy Sequencing and Patient Selection in Prostate Cancer Treatment

July 29th 2022

Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.